Streetbeat News

Price Targets

CSIQ

UBS analyst Jon Windham has maintained a 'Buy' rating on Canadian Solar (NASDAQ:CSIQ) but lowered the price target from $50 to $47.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:30 pm

GLPI

UBS analyst Robin Farley maintains a Buy rating on Gaming and Leisure Props (NASDAQ:GLPI) and raises the price target from $55 to $56.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:29 pm

BRZE

UBS analyst Taylor McGinnis maintains a Neutral rating on Braze (NASDAQ:BRZE) and raises the price target from $38 to $44.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:29 pm

WMB

Morgan Stanley analyst Robert Kad has maintained an Equal-Weight rating on Williams Companies (NYSE:WMB) and raised the price target from $39 to $42.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:21 pm

WES

Morgan Stanley analyst Robert Kad has maintained an Overweight rating on Western Midstream (NYSE:WES) but lowered the price target from $36 to $34.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:20 pm

VTYX

Morgan Stanley analyst Simon Flannery has maintained an Overweight rating on Ventyx Biosciences (NASDAQ:VTYX) and raised the price target from $45 to $46.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:19 pm

TRGP

Morgan Stanley analyst Robert Kad maintains an Overweight rating on Targa Resources (NYSE:TRGP) and raises the price target from $106 to $114.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:18 pm

SKX

Morgan Stanley analyst Alex Straton has maintained an Equal-Weight rating on Skechers USA (NYSE:SKX) and raised the price target from $48 to $49.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:15 pm

SPG

JP Morgan analyst Anthony Paolone has maintained a Neutral rating on Simon Property Group (NYSE:SPG) and lowered the price target from $125 to $124.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 1:15 pm

RGNX

Morgan Stanley analyst Vikram Purohit has maintained an Overweight rating on Regenxbio (NASDAQ:RGNX) but lowered the price target from $43 to $42.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 1:12 pm